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Clinically isolated syndrome (CIS) is a first episode of neurological symptoms that may 
precede a diagnosis of multiple sclerosis (MS). Therefore, studying individuals with CIS 
may lead to breakthroughs in understanding the development and pathogenesis of MS. 
In this study, serum levels of immunoglobulin (Ig)G, IgA, IgM, and IgG1–4 were mea-
sured in 20 people with CIS and compared with those in 10 healthy controls (HC) and 8 
people with MS. Serum Ig levels in individuals with CIS were compared with (a) the time 
to their conversion from CIS to MS, (b) serum levels of antibodies to Epstein–Barr virus, 
(c) frequencies of T regulatory (Treg), T follicular regulatory (Tfr), and B cell subsets, and 
(d) Treg/Tfr expression of Helios. Serum IgG, IgM, and IgG2 levels were significantly lower 
in people with CIS than HC, and IgG, IgM, and IgG1 levels were significantly lower in 
people with CIS than MS. After adjusting for age, sex, and serum 25(OH) vitamin D3 
[25(OH)D] levels, CIS was associated with lower serum levels of IgG and IgG2 compared 
with HC (p = 0.001 and p < 0.001, respectively). People with MS had lower IgG2 levels 
(p < 0.001) and IgG2 proportions (%IgG; p = 0.007) compared with HC. After adjusting for 
age, sex, and 25(OH)D, these outcomes remained, in addition to lower serum IgA levels 
(p = 0.01) and increased IgG3 levels (p = 0.053) in people with MS compared with HC. 
Furthermore, serum from people with MS had increased proportions of IgG1 and IgG3 
(p = 0.03 and p = 0.02, respectively), decreased proportions of IgG2 (p = 0.007), and 
greater ratios of “upstream” to “downstream” IgG subclasses (p = 0.001) compared with 
HC. Serum IgG3 proportions (%IgG) from people with CIS correlated with the frequency 
of plasmablasts in peripheral blood (p = 0.02). Expression of Helios by Treg and Tfr cell 
subsets from individuals with CIS correlated with levels of serum IgG2 and IgG4. IgG3 
levels and proportions of IgG3 (%IgG) in serum at CIS diagnosis were inversely correlated 
with the time until conversion to MS (p = 0.018 and p < 0.001, respectively), suggesting 
they may be useful prognostic markers of individuals with CIS who rapidly convert to MS.
Keywords: clinically isolated syndrome, multiple sclerosis, immunoglobulin, antibody, biomarkers
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INTRODUCTION
Clinically isolated syndrome (CIS) is often a precursor to multiple 
sclerosis (MS), an immune-mediated inflammatory and degen-
erative neurological condition with complex etiology involving 
both genetic and environmental factors. Almost all people with 
MS have evidence of past infection with Epstein–Barr virus (EBV) 
(1). Smoking and low past exposure to ultraviolet radiation are 
also environmental risk factors for MS (2). The disease course 
following a diagnosis of CIS varies greatly between individuals, 
with the majority eventually converting to MS (3).
There are currently no reliable biomarkers available to indicate 
prognosis at CIS presentation, though earlier age at onset, having 
more lesions detected by magnetic resonance imaging (MRI) at 
diagnosis, and presence of oligoclonal bands in the cerebrospinal 
fluid (CSF) are associated with an increased absolute risk of 
conversion from CIS to MS (4–6). Earlier treatment is associated 
with decreased morbidity (7), and, as such, identifying predictive 
biomarkers for disease course early in MS is a research priority 
(8). Identification of peripheral blood biomarkers that indicate 
the expected length of time until conversion to MS would be 
valuable, given the relatively low invasiveness of blood compared 
with CSF sampling (9). New biomarkers of MS could also identify 
mediators of inflammation in early disease, which is important 
since the exact cause of MS is unknown.
While many cellular and humoral immune mediators may 
be associated with early inflammatory disease in MS, B  cells 
and their products are of particular interest. Ectopic lymphoid 
follicles are found in the central nervous system of some people 
with MS. These structures contain B cells and immunoglobulin 
(Ig)G antibodies (10–12). Although antibodies are likely to be 
important in MS development, unlike other idiopathic inflamma-
tory demyelinating disorders such as neuromyelitis optica, where 
aquaporin-4-specific IgG antibody levels are a highly sensitive 
measure to classify disease and predict relapse (13), no disease-
specific MS-antigen has been identified. As such, MS appears to 
be mediated to some extent by heterogeneous auto-antibodies 
targeted against neurological antigens (14).
In this study, levels of total IgG, IgA, IgM, and IgG subclasses 
were investigated in the serum of individuals recently diagnosed 
with CIS and compared with healthy controls (HC) and people 
with definite MS. We hypothesized that increased levels of one or 
more Ig isotype would be present in serum from people with CIS 
and MS compared with HC, and that higher serum Ig levels at the 
time of CIS diagnosis would be associated with a shorter time to 
conversion to MS.
MATERIALS AND METHODS
Study Participants
This study involved participants of the PhoCIS study (n = 20), 
a trial of narrowband UVB phototherapy (311–312  nm) for 
the prevention of conversion from CIS to MS in a high-risk 
cohort (15). CIS participants were <120  days from their first 
demyelinating event at study enrollment. All participants with 
CIS were drug–naïve and blood samples were collected prior to 
the UVB phototherapy intervention. Participants were followed 
up at 3, 6, and 12 months after enrollment using MRI to detect 
conversion to MS.
Samples from eight people with definite MS and recent clini-
cal symptoms who had not been treated with disease-modifying 
therapies or steroids in the previous 30 days were collected as a 
comparison group. Seven MS individuals were newly diagnosed 
(venepuncture within 22 days of diagnostic MRI) and one indi-
vidual was diagnosed with MS 7  years ago with a recent MRI 
relapse. Both CIS and MS were diagnosed according to the 2010 
McDonald diagnostic criteria (16), with CIS meeting or exceed-
ing PatyA or PatyB criteria.
In addition, a cohort of non-CIS control participants (n = 10) 
were recruited to examine seasonal serum vitamin D levels (HC) 
and utilized as a comparison group. The HC had no history of 
autoimmune disease.
This study was carried out in accordance with the recommen-
dations of the National Health and Medical Research Council 
of Australia’s National Statement on Ethical Conduct in Human 
Research. The PhoCIS study protocol was approved by the 
Bellberry Human Research Ethics committee (2014-02-083) and 
endorsed by the Human Research Ethics Office of the University 
of Western Australia (RA/4/1/6796), and the study of MS par-
ticipants was approved by Sir Charles Gairdner Hospital Human 
Research Ethics Committee (2006-073). All participants gave 
written informed consent in accordance with the Declaration of 
Helsinki prior to study procedures being performed.
Blood Samples
Peripheral venous blood was collected from individuals with CIS 
and extensive phenotypes of peripheral blood mononuclear cells 
(PBMCs) were obtained by multicolor flow cytometry as previ-
ously described (17, 18). Blood was also collected in Vacutainer 
SST tubes (Becton Dickinson, North Ryde, NSW, Australia) and 
serum separated by centrifugation at 800 × g for 10 min, then 
stored at −80°C until batch analyses.
Serum was also collected in the same manner from HC 
monthly for 12 months, and as a one-off sample from individuals 
with MS.
Serum Ig Assays
Total IgG, IgG2, IgG3, IgG4, total IgA, and IgM were measured 
using cytometric bead arrays (BD Biosciences, North Ryde, NSW, 
Australia), with data captured using the BD LSRFortessa flow 
cytometer, according to the manufacturer’s instructions. IgG2, 
IgG3, and IgG4 levels were calculated both as absolute concentra-
tions (μg/mL) and as a percentage of total IgG. Since IgG1 was not 
measured in the bead array assay (due to it becoming unavailable 
in the BD product range), IgG1 levels and proportions (as % of 
total IgG) were calculated by subtracting the measured concen-
trations of IgG2, IgG3, and IgG4 from total IgG in the cytometric 
bead arrays.
The reliability of the calculated IgG1 levels was confirmed 
by measuring IgG1 levels using enzyme-linked immunosorbent 
assays (ELISA; Abcam, Melbourne, VIC, Australia). Although 
the IgG1 values determined by each method were significantly 
correlated (intraclass correlation = 0.542, p = 0.02), the levels of 
IgG1 reported by ELISA were consistently lower than expected. 
TABLE 1 | Characteristics of the healthy controls (HC), people with clinically isolated syndrome (CIS) or multiple sclerosis (MS) included in the dataset.
HC (n = 10) CIS (n = 20) MS (n = 8) p-Value
Age [median (minimum–maximum)] 35.4 (25.5–46.9) 38.0 (23.4–54.3) 45.0 (18.4–54.6) 0.64
Female sex [n (%)] 8 (80) 12 (60) 5 (62.5) 0.54
Serum 25(OH)D (nmol/L) [median (minimum–maximum)] 67.7 (37.9–84.9)* 88.5 (43.7–135.6)* 76.5 (40.8–108.2) 0.04
EBV status
Anti-viral capsid antigen IgG [U/mL; median (minimum–maximum)] ND 289 (73.8–750#) 550.5 (72.8–750#) 0.12
Anti-EBV nuclear antigen-1 IgG [U/mL; median (minimum–maximum)] ND 600 (159–600#) 426 (38.8–600#) 0.86
Time since diagnosis of CIS or MS (days) [median (minimum–maximum)] n/a 36.5 (−1 to 94)* 6 (0–2,537)* <0.001
Superscript letter indicates groups which were significantly different to one another in post-test.
Bold font and shading indicates a statistically significant p value.
*Lower limit of detection of assay.
#Upper limit of detection of assay.
n/a, not applicable; ND, not done; EBV, Epstein–Barr virus.
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Therefore, IgG1 levels and proportion data (%IgG) presented here 
were those calculated from results of the cytometric bead array 
assays.
Measurement of Serum 25(OH) Vitamin D3 
and EBV Serology
Serum 25(OH) vitamin D3 [25(OH)D] was measured by liquid 
chromatography tandem mass spectroscopy (19). The con-
centration of anti-EBV antibodies (anti-Viral Capsid Antigen 
IgG, Anti-EBV nuclear antigen-1 IgG, and anti-EBV IgM) was 
measured in serum from people with CIS and MS by PathWest 
Laboratory Medicine (Nedlands, WA, Australia).
B Cell, T Regulatory (Treg), and T Follicular 
Regulatory (Tfr) Cell Subset Frequencies 
in CIS Individuals
B  cell, Treg, and Tfr subset frequencies and Treg/Tfr levels of 
Helios expression in the blood samples from 18 of the 20 indi-
viduals in the CIS cohort were previously reported (17, 18). In 
this study, data from two additional blood donors with CIS were 
included and analyzed as previously described.
Statistical Analyses
The data presented for HC [Ig and 25(OH)D] were mean values 
calculated from serial blood samples collected monthly for 
12 months. Data were examined by season (Summer = December–
February, Autumn =  March–May, Winter =  June–August, and 
Spring  =  September–November). No significant differences 
between seasonal Ig levels were detected in HC serum collected 
over 1  year using Friedman tests (Figure S1 in Supplementary 
Material), but seasonal serum 25(OH)D levels were significantly 
lower in winter months than in summer months (data not shown).
Spearman’s rho (ρ) was used to test the correlation between 
the Ig levels and other continuous variables. Mann–Whitney U 
tests were used to compare continuous outcomes in people with 
CIS, MS, and HC, and Fisher’s exact test was used for categorical 
variables. The ratio of “upstream”:“downstream” IgG subclasses 
was calculated by adding the frequencies of measured IgG3 (%IgG) 
and calculated IgG1 (%IgG) together and dividing by the combined 
frequencies of measured IgG2 (%IgG) and measured IgG4 (%IgG).
Correlation between ELISA and cytometric bead array-
determined values of serum IgG1 was tested using intraclass 
correlation, with the average measures intraclass correlation 
coefficient reported.
Generalized linear models were used to examine the effects of 
CIS and MS, compared with HC, on Ig levels, adjusting the data 
for 25(OH)D levels, sex, and age. Data analyses were performed 
using SPSS software (IBM Corp., v24). For all analyses, a p-value 
<0.05 was considered to be statistically significant.
RESULTS
Demographics of Participating Blood 
Donors
The demographics of the HC and people with CIS and MS are 
shown in Table 1. Individuals in each group were similar in sex 
and age, but people with CIS had significantly higher serum 
25(OH)D levels than HC (Table 1). All individuals with CIS and 
MS had evidence of past EBV infection, indicated by positive 
IgG serology tests. Eighteen people with CIS had no detectable 
anti-EBV IgM in serum, and two had equivocal levels, suggest-
ing that there were no cases of recent EBV infection. Of the eight 
individuals with definite MS, six had no detectable anti-EBV 
IgM in their serum, one had a positive test, and one had an 
equivocal result.
Different Serum Ig Profiles Between HC, 
and CIS and MS Individuals
The levels of total measured Ig isotypes, IgG subclasses, and IgG 
subclasses as proportions of total IgG are shown in Figures 1A–C, 
Figures  2A–D, and Figures  3A–D, respectively. There were 
significantly lower serum levels of total IgG and IgM in people 
with CIS relative to both HC and people with MS (Figures 1A,C). 
In both the CIS and MS groups, serum IgA levels were non-
significantly lower than in HC (p = 0.07 and p = 0.06, respec-
tively; Figure 1B). When subclasses of IgG were examined, levels 
of IgG1 were significantly higher in people with MS than those 
with CIS (Figure 2A), and IgG2 levels were significantly lower 
in serum from people with both CIS and MS compared with HC 
(Figure 2B). In people with MS, IgG2 proportions (%IgG) were 
also significantly lower than in HC (Figure 3B). The relative pro-
portions of IgG1, IgG3, and IgG4 and absolute levels of IgG3 and 
IgG4 (as %IgG) were not significantly different between groups. 
However, the ratios of “upstream” (IgG3 + IgG1) to “downstream” 
FIGURE 1 | Total IgG (A), IgA (B), and IgM (C) concentrations in serum from 
healthy controls (HC) averaged over a 1-year collection period (n = 10; open 
bars) compared with people with recently diagnosed clinically isolated 
syndrome (CIS) (n = 20; shaded bars) and multiple sclerosis (MS) (n = 8, 
diagonal lines in bars). Individual values are shown and group medians are 
indicated by the horizontal bar. Statistically significant comparisons in 
Mann–Whitney tests (p < 0.05) are indicated with as asterisk.
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(IgG2 + IgG4) IgG subclasses were significantly higher in the MS 
group than in HC (Figure 4).
As the CIS and HC blood donors had different serum 25(OH)
D levels (Table 1), and Ig levels can differ according to age and 
sex (20), the differences in Ig levels detected between the groups 
could have been confounded by these variables. Therefore, 
generalized linear models were used to compare Ig levels between 
the CIS and MS individuals and HC while simultaneously adjust-
ing for these other potentially related predictor variables. When 
Ig data were adjusted for serum 25(OH)D levels, sex and age in 
the models, total IgG in CIS and IgG2 levels in both CIS and 
MS remained significantly lower than those in HC (Table  2), 
confirming the results of the univariable analyses. Differences in 
serum IgM levels between CIS and HC detected using the raw 
data were not significant after adjusting data for age, sex, and 
25(OH)D. Total IgA levels remained non-significantly lower in 
CIS compared with HC (p = 0.069) but unlike in the univariate 
comparison, relative to HC, people with MS were associated with 
significantly lower serum IgA levels and significantly higher IgM 
levels after adjusting for other variables. IgG3 levels in people 
with MS were non-significantly increased compared with HC 
(p = 0.053). Furthermore, after adjusting for age, sex, and 25(OH)
D, MS was associated with significantly increased proportions of 
IgG1 and IgG3, and decreased proportions of IgG2 (as % of total 
IgG), resulting in a significantly greater ratio of “upstream” to 
“downstream” IgG subclasses.
Combining all participant groups and adjusting for the effects 
of CIS, sex, and serum 25(OH)D levels, absolute IgG3 levels were 
significantly inversely associated with age, and lower IgM levels 
with male sex. There were no associations between Ig levels and 
25(OH)D levels.
In summary, compared with HC after adjustment for pos-
sible confounders, CIS was associated with lower serum levels of 
total IgG and IgG2. MS was associated with lower serum levels 
of IgG2 and IgA, increased levels of IgM, decreased proportions 
of IgG2, and increased proportions of “upstream” IgG subclasses 
IgG3 and IgG1.
Serum IgG3 Levels Inversely Correlated 
With Time to MS Conversion
Since prognostic markers of conversion to MS would be highly 
valuable in people with newly diagnosed CIS, correlations were 
investigated between the serum Ig levels of people with CIS and 
the number of days until conversion to MS. Conversion from CIS 
to MS within 12  months of collection of blood was confirmed 
by MRI in 16 of the 20 people with CIS. 3 of the 20 people with 
CIS had not converted after 12  months, and one was lost to 
follow-up after 2 months (15). Analyses of serum samples from 
the individuals with known outcomes showed that higher levels 
of IgG3 (Figure 5A) and a higher proportion of IgG3 (as %IgG; 
Figure 5B) in serum close to CIS diagnosis were inversely cor-
related with the number of days to conversion from CIS to MS 
(Figure 5). This association was maintained for both predictors 
when adjusted for serum 25(OH)D levels, age, and sex in regres-
sion analyses (data not shown). A weaker positive correlation 
was also observed for serum IgG2 levels and time to conversion 
(ρ = 0.52, p = 0.04), but the association was not maintained in 
regression analyses adjusting for 25(OH)D levels, age, and sex.
Correlations Between Serum EBV-Specific 
Antibodies and Serum Ig Levels
Since elevated IgG antibody levels against EBV are associated 
with an increased MS risk (21) and EBV-specific antibodies are 
FIGURE 2 | Serum concentrations of IgG subclasses, (A) IgG1, (B) IgG2, (C) IgG3, and (D) IgG4 from healthy controls (HC) averaged over a 1-year collection 
period (n = 10; open bars) compared with people with recently diagnosed clinically isolated syndrome (CIS) (n = 20; shaded bars) and multiple sclerosis (MS) (n = 8, 
diagonal lines in bars). Individual values are shown and group medians are indicated by the horizontal bar. Statistically significant comparisons in Mann–Whitney 
tests (p < 0.05) are indicated with as asterisk and very significant comparisons (p < 0.01) are indicated with two asterisks.
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predominantly of the IgG1 and IgG3 subclasses (22), serum 
levels of antibodies against EBV were investigated for correla-
tions with Ig levels, including IgG3. No correlations were found 
between with the levels of total IgG, IgA, IgM, or IgG subclasses 
and EBV antibodies in serum from people with CIS (data not 
shown).
Correlations Between Serum Ig and PBMC 
Subset Frequencies and Helios Expression 
in Tregs
Earlier work from this laboratory investigated differences in 
PBMC subsets between HC (a different cohort than those 
reported here) and those with CIS (17, 18). The frequencies of 
transitional B cells and CD1c + B cells were increased in peo-
ple with CIS compared with HC (18). Treg and Tfr cells were 
categorized into different fractions according to FoxP3 and 
CD45RA expression (17), which is a more advanced dissection 
of Tregs originally described by Sakaguchi and colleagues (23), 
as well as by their expression of Helios, a key transcription 
factor associated with Treg functions (24). Treg and Tfr cell 
frequencies and Treg/Tfr cells with low Helios expression were 
identified as subsets differentiating CIS from HC. Therefore, 
B cell subsets and Treg/Tfr subsets were tested for correlation 
with levels of serum Ig in people with CIS.
B Cell Frequencies
Serum Ig concentrations in people with CIS were tested for cor-
relation with the frequencies of total B cells, transitional B cells, 
memory B cells, and plasmablasts in peripheral blood (cellular 
phenotypes are described in Table 3). There was no correlation 
between the frequency of total B cells (%PBMC) and the concen-
trations of any Ig in serum (data not shown). However, switched 
memory B cell frequencies (%B cells) positively correlated with 
IgG1 proportions (%IgG), and inversely correlated with IgG2 
proportions (%IgG) (Table  3). In addition, the frequency of 
plasmablasts (%B  cells) was positively correlated with IgG3 
proportions (%IgG). There was a non-significant correlation 
between the proportion of IgG3 (%IgG) and the frequency of 
double-negative memory B cells (Table 3).
FIGURE 3 | Proportions of calculated (A) IgG1, (B) IgG2, (C) IgG3, and (D) IgG4 subclasses as a percent of total IgG shown in Figure 1 from healthy controls (HC) 
(n = 10; open bars) compared with people with recently diagnosed clinically isolated syndrome (CIS) (n = 20; shaded bars) and multiple sclerosis (MS) (n = 8, 
diagonal lines in bars). Individual values are shown and group medians are indicated by the horizontal bar. Statistically significant comparisons in Mann–Whitney 
tests (p < 0.05) are indicated with as asterisk.
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Treg and Tfr Cell Frequencies and Helios Expression
Total IgG levels were inversely correlated with cytokine-producing 
non-Treg (FrIII) frequencies, as shown in Table  4 (cellular 
phenotypes are described in Table 4). The expression of Helios 
(quantified as geometric mean fluorescence intensity; MFI) in 
several Treg and Tfr fractions was significantly correlated with 
total IgG, IgG2, and IgG4 in serum (Table  5). However, IgG3 
subclass levels were independent of Helios expression in people 
with CIS.
DISCUSSION
In a key finding of this work, IgG3 levels and proportions of IgG3 
(%IgG) in serum were identified as a potential prognostic marker 
for people with CIS who rapidly convert to MS. The detection of 
≥9 lesions by MRI is a marker of people with CIS who are likely to 
convert to MS (4). However, in this study, an inverse correlation 
between serum IgG3 levels and time until MS conversion was 
observed, suggesting the potential of serum IgG3 to complement 
the categorical risk assessment from using MRI data, and 
incorporate the dimension of time in the prognostic assessment 
when an individual presents with CIS. Moreover, although CSF 
oligoclonal bands are used as a prognostic marker in MS, most of 
our CIS participants did not have CSF collected, highlighting the 
benefit of a developing a blood-based prognostic test for people 
with CIS. The potential prognostic capacity of serum IgG3 levels 
in people with CIS should be confirmed in a larger cohort. The 
strength of this research was the inclusion of individuals with 
high-risk CIS, where most converted to MS within 12  months 
of diagnosis. This is a population that is rarely studied but is 
important to include in research to understand how MS develops.
People with definite MS exhibited higher serum proportions 
of IgG3 (%IgG) and lower serum IgG2 levels than HC in the 
adjusted analysis, suggesting that these abnormalities are markers 
of B  cell dysfunction associated with the immunopathogenesis 
of MS. These findings indicate that although total IgG levels are 
lower in CIS compared with HC, presumably reflecting IgG2 
deficiency, the relative proportions of cells secreting IgG3 may 
FIGURE 4 | Ratios of calculated IgG1 (%IgG) + IgG3 (%IgG) to IgG2 
(%IgG) + IgG4 (%IgG) in serum from healthy controls (HC) averaged over  
a 1-year collection period (n = 10; open bars) compared with people with 
recently diagnosed clinically isolated syndrome (CIS) (n = 20; shaded bars) 
and multiple sclerosis (MS) (n = 8, diagonal lines in bars). Individual values are 
shown and group medians are indicated by the horizontal bar. Statistically 
significant comparisons in Mann–Whitney tests (p < 0.05) are indicated with 
as asterisk.
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be increased compared with those secreting IgG2 in MS. Serum 
IgG3 levels in people with CIS correlated with proportions of cir-
culating plasmablasts (CD19+CD20−CD38hiCD27hiIgD−CD24−), 
cells which are increased in the CSF of people with MS 
(25). Non-significant correlation between the frequency of 
CD19+CD27−IgD− cells (%B cells) and proportion of serum IgG3 
(%IgG) was observed in people with CIS. Supporting this finding, 
cells with a similar CD19+CD27−IgG+ phenotype were reported 
to produce relatively high amounts of IgG3 and low amounts of 
IgG2 (26). However, the secretory activities of specific circulating 
cell subsets were not tested in this study. IgG3 has stronger affin-
ity for the activatory Fcγ receptors, FcγRIIA and FcγRIIIA, on 
immune cells than the “downstream” subclasses, IgG2 and IgG4 
(27, 28). Therefore, IgG3 could actively contribute to systemic 
pro-inflammatory immune responses in CIS and MS. This study, 
as well as those demonstrating the different effects of FcγR allele 
variants on therapeutic responses and prognosis in MS and other 
immune-mediated diseases (29–32), suggest that the effects of 
increased IgG3 proportions in serum on the immune cells that 
express FcγRs warrant further investigation in MS.
Several explanations for the association of higher serum 
IgG3 proportions with a faster rate of conversion from CIS 
to MS are worthy of consideration. First, this might reflect a 
relative predominance of IgG3 antibodies to myelin oligoden-
drocyte glycoprotein (11) as part of the postulated involve-
ment of auto-antibodies in mediating MS demyelination (33). 
Second, it might indicate an active antibody response against a 
viral pathogen, such as EBV, that triggers an immune response 
against myelin. However, a relationship between serum IgG3 
and serum levels of antibodies to EBV was not found in this 
study. Finally, it is possible that the decreased serum IgG2 levels 
in people with both CIS and MS, increased proportions of IgG3 
and IgG1 in people with MS [after adjustment for age, sex, and 
25(OH)D], and the inverse correlation of serum IgG3 propor-
tions (%IgG) with time to conversion from CIS to MS may 
reflect an acquired immunoregulatory defect, similar to that 
which has been described in chronic human immunodeficiency 
virus infection (34).
In people with MS, there was a shift in proportions of IgG 
subclasses as a percentage of total IgG compared with HC, 
with increased proportions of “upstream” IgG3 and IgG1 and 
decreased proportions of the “downstream” IgG2 subclass. No 
differences between IgG4 levels were detected between groups, 
perhaps reflecting the minor contribution of this IgG subclass to 
total IgG levels in serum. Sequential class switch recombination 
of heavy chain genes during B cell differentiation in germinal 
center reactions initially results in production of antibodies of 
“upstream” isotypes IgM, IgG3, and IgG1, followed by those of 
“downstream” isotypes IgA1, IgG2, and IgG4 (35). Therefore, 
the combination of increased IgM in MS, increased proportions 
of IgG3 and IgG1 in MS, and decreased IgG2 and IgA levels 
in CIS and MS suggest that dysregulation of antibody isotype 
diversification is occurring in people with high-risk CIS and 
MS. This may result from decreased B cell maturation activity in 
germinal centers (36), and subsequent decreases in the frequen-
cies of mature cells producing downstream IgG subclasses. There 
was an increased frequency of transitional B  cells detected in 
people with CIS compared with HC (18); transitional B cells in 
this study had some identifying characteristics congruent with 
the functionally immature B  cell phenotype reported to have 
limited capacity for Ig production (37). Given the importance of 
CD40 for class switching to occur in germinal centers (38), and 
the finding of decreased B cell CD40 expression in association 
with the MS risk allele rs4810485*T (39), we suggest that there 
may be impairment of normal class switching in CIS and MS 
mediated, in part, by a reduction in CD40–CD40L engagement 
on maturing B cells.
It was hypothesized that people with CIS would have increased 
serum levels of Ig compared with healthy individuals. However, 
both total IgG and IgM were lower in CIS compared with HC. 
Although most of the people with CIS converted to MS, low IgM 
and IgG were not detected in the MS group, suggesting the secre-
tory functions of antibody-secreting cells in people with CIS may 
be transiently impaired for reasons that are unclear. Reports in 
the literature on Ig levels in MS have been variable; people with 
MS have been described to have similar serum Ig levels compared 
with controls (40), higher IgA and lower IgM in MS compared 
with HC (41), or lower levels of total IgG and IgG4 (42). The people 
with CIS and MS in our cohort represent a different population 
to those in previous studies, where participants had established 
MS. Moreover, the small number of individuals studied in the MS 
group may limit the generalizability of these findings to a broader 
MS cohort, particularly those with long-established disease, who 
were not well represented in our study.
Given that Tregs can suppress antibody responses (43) and 
our previous findings indicated that they are functionally 
impaired in CIS (17), it was proposed that the levels of Treg and 
Tfr subsets and their relative Helios expression may inversely 
8
Trend et al. Serum Igs in MS
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1590
TABLE 2 | Results of regression analyses for serum immunoglobulin levels, adjusting for clinical variables.
Outcome variable Independent variable Unadjusted estimate 95% Confidence interval p-Value
Lower Upper
Total IgG (μg/mL) MS vs. HC −1,703.39 −5,511.1 2,104.33 0.38
CIS vs. HC −5,574.52 −8,966.63 −2,182.41 0.001
Male vs. female sex −606.79 −3,324.34 2,110.76 0.66
Age −57.68 −202.69 87.33 0.44
25(OH)D 13.99 −45.57 73.56 0.65
IgA (μg/mL) MS vs. HC −1,352.97 −2,427.85 −278.09 0.014
CIS vs. HC −887.93 −1,845.49 69.63 0.069
Male vs. female sex 259.36 −507.78 1,026.50 0.51
Age −31.69 −72.63 9.24 0.13
25(OH)D 6.652 −10.16 23.47 0.44
IgM (μg/mL) MS vs. HC 502.84 54.34 951.34 0.028
CIS vs. HC −209.65 −609.19 189.90 0.30
Male vs. female sex −494.65 −814.74 −147.55 0.002
Age −2.38 −19.46 14.70 0.785
25(OH)D −6.03 −13.05 0.99 0.09
Calculated IgG1 (μg/mL) MS vs. HC 1,213.67 −1,957.62 4,384.96 0.45
CIS vs. HC −2,523.73 −5,348.88 301.42 0.08
Male vs. female sex −591.83 −2,855.17 1,671.51 0.61
Age −25.95 −146.72 94.82 0.67
25(OH)D 4.75 −44.86 54.36 0.85
IgG2 (μg/mL) MS vs. HC −3,177.1 −4,718.33 −1,635.86 <0.001
CIS vs. HC −2,693.94 −4,066.95 −1,320.93 <0.001
Male vs. female sex 161.04 −938.94 1,261.01 0.77
Age −7.50 −66.19 51.20 0.8
25(OH)D 4.48 −19.63 28.59 0.72
IgG3 (μg/mL) MS vs. HC 544.22 −7.10 1,095.54 0.053
CIS vs. HC −162.53 −653.67 328.62 0.52
Male vs. female sex −286.54 −680.01 106.94 0.15
Age −24.77 −45.76 −3.77 0.02
25(OH)D 4.14 −4.48 12.77 0.35
IgG4 (μg/mL) MS vs. HC −284.18 −635.05 66.69 0.11
CIS vs. HC −194.32 −506.89 118.25 0.22
Male vs. female sex 110.54 −139.88 360.95 0.39
Age 0.53 −12.83 13.89 0.94
25(OH)D 0.62 −4.87 6.11 0.83
Calculated IgG1 (%IgG) MS vs. HC 16.25 0.84 31.66 0.03
CIS vs. HC 3.74 −9.99 17.47 0.59
Male vs. female sex −2.49 −13.49 8.51 0.66
Age −0.08 −0.66 0.51 0.80
25(OH)D 0.06 −0.19 0.30 0.66
IgG2 (%IgG) MS vs. HC −19.9 −34.33 −5.47 0.007
CIS vs. HC −6.29 −19.14 6.56 0.34
Male vs. female sex 1.20 −9.10 11.5 0.82
Age 0.19 −0.36 0.74 0.51
25(OH)D −0.06 −0.28 0.17 0.62
IgG3 (%IgG) MS vs. HC 5.00 0.69 9.31 0.02
CIS vs. HC 2.14 −1.70 5.98 0.28
Male vs. female sex −0.33 −3.40 2.75 0.84
Age −0.16 −0.33 0.003 0.054
25(OH)D 0.02 −0.05 0.09 0.60
IgG4 (%IgG) MS vs. HC −1.36 −4.36 1.64 0.38
CIS vs. HC 0.41 −2.26 3.08 0.76
Male vs. female sex 1.62 −0.52 3.76 0.14
Age 0.05 −0.06 0.16 0.39
25(OH)D −0.02 −0.06 0.03 0.52
(Continued )
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FIGURE 5 | Inverse correlation between time to relapse [conversion from 
clinically isolated syndrome (CIS) to multiple sclerosis] and (A) proportions of 
IgG3 (%IgG) or (B) IgG3 levels in serum from people with CIS (n = 16). 
Serum was collected within 120 days of CIS diagnosis and individuals were 
followed for 12 months using magnetic resonance imaging to determine date 
of relapse. IgG3 was measured using cytometric bead arrays. Spearman 
correlation is shown using Spearman’s rho (ρ), alongside p-values.
Outcome variable Independent variable Unadjusted estimate 95% Confidence interval p-Value
Lower Upper
Ratio of IgG1 + IgG3: 
IgG2 + IgG4
MS vs. HC 3.09 1.18 4.99 0.001
CIS vs. HC 0.60 −1.10 2.30 0.49
Male vs. female sex −0.45 −1.81 0.91 0.52
Age −0.01 −0.09 0.06 0.74
25(OH)D 0.01 −0.02 0.04 0.54
Table shows unadjusted parameter estimates with 95% CIs.
Statistically significant p-values are indicated by bolded font and shading.
p-Values <0.05 indicates a p-value between 0.01 and 0.05.
CI, confidence interval; CIS, clinically isolated syndrome; HC, healthy controls; MS, multiple sclerosis.
TABLE 2 | Continued
correlate with Ig levels in serum. Rather, IgG2 and IgG4 levels 
in serum were positively associated with Helios expression in 
Treg and Tfr, but IgG3 levels were not related to the extent 
of Helios expression or to the frequencies of Treg subsets. 
Future studies should confirm whether the relative increases 
of IgG3 antibodies in people with high-risk CIS are dependent 
on changes in Treg functionality or other aspects of immune 
regulation. Although low serum 25(OH)D has been associated 
with an increased risk of MS (44), this cohort was character-
ized by vitamin D sufficiency [25(OH)D > 50 nmol/L] in all 
but one individual with CIS, and yet most converted to MS. In 
addition, no associations were found between 25(OH)D and Ig 
levels in serum, although this study was not designed to spe-
cifically investigate this association. IgG production in vitro by 
plasma cells is reported to be limited by 1,25(OH)2D3 (45). In 
vivo, positive or negative associations between 25(OH)D levels 
and/or season and IgG levels in serum are variously reported 
(46–48) but in people with MS, no association between 
vitamin D and serum or intrathecal IgG has been reported 
(49, 50). Research intended to investigate the effects of vitamin 
D metabolites on Ig production in plasma cells from people 
with MS may resolve whether there is significant interaction 
between these factors.
The major findings of this study were that lower serum levels 
of IgG2, and total IgG (which can be partially explained by 
lower IgG2 levels) were detected in drug–naïve people recently 
diagnosed with CIS compared with HC, and that there was an 
association between higher serum IgG3 levels at CIS diagnosis 
and earlier conversion to MS. The decrease in serum IgG2 was 
confirmed in people with MS, but in the absence of changes in 
total IgG levels, this resulted in higher ratios of “upstream” to 
“downstream” IgG subclasses compared with HC. Based on these 
findings, it can be hypothesized that impaired antibody class 
switching in germinal centers might be occurring in people with 
MS. This study suggests that serum IgG3 levels and/or propor-
tions of total IgG could be an indicator of disease prognosis and 
might be used to guide the use of future immune therapies in 
people with CIS. This could be tested in clinical trials. As serum Ig 
levels in people with CIS did not correlate with levels of anti-EBV 
antibodies, there appears to be an expansion of IgG3-secreting 
cells with unknown antigen specificity or clonality which should 
be investigated.
10
Trend et al. Serum Igs in MS
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1590
T
A
B
L
E
 3
 |
 A
 c
o
m
p
a
ri
s
o
n
 o
f 
a
b
s
o
lu
te
 s
e
ru
m
 l
e
v
e
ls
 (
μg
/m
L
) 
a
n
d
 p
ro
p
o
rt
io
n
s
 o
f 
Ig
G
 s
u
b
c
la
s
s
e
s
 (
%
Ig
G
) 
v
s
. 
%
B
 c
e
lls
 i
n
 i
n
d
iv
id
u
a
ls
 w
it
h
 c
lin
ic
a
lly
 i
s
o
la
te
d
 s
y
n
d
ro
m
e
 (
n
 =
 2
0
).
%
 B
 c
e
ll
s
P
h
e
n
o
ty
p
e
S
ta
ti
s
ti
c
Ig
A
Ig
M
T
o
ta
l 
Ig
G
C
a
lc
u
la
te
d
  
Ig
G
1
Ig
G
2
Ig
G
3
Ig
G
4
C
a
lc
u
la
te
d
  
Ig
G
1
%
 I
g
G
Ig
G
2
%
 I
g
G
Ig
G
3
%
Ig
G
Ig
G
4
%
 I
g
G
T
ra
n
s
it
io
n
a
l 
B
 c
e
lls
C
D
1
9
+ C
D
2
0
+ C
D
2
7
− I
g
D
+ C
D
2
4
h
i C
D
3
8
h
i
ρ
−0
.2
5
−0
.2
8
−0
.4
1
−0
.4
0
−0
.1
2
−0
.3
6
0
.1
5
−0
.1
0
0
.1
4
0
.0
4
0
.2
8
p
-V
a
lu
e
0
.3
0
0
.2
4
0
.0
8
0
.0
8
0
.6
3
0
.1
2
0
.5
3
0
.6
5
0
.5
6
0
.8
6
0
.2
3
S
w
it
c
h
e
d
 m
e
m
o
ry
  
B
 c
e
lls
C
D
1
9
+ C
D
2
0
+ C
D
2
7
+ I
g
D
−
ρ
−0
.2
5
−0
.2
3
0
.1
0
0
.2
3
−0
.3
4
0
.0
8
−0
.1
7
0
.5
5
−0
.4
7
−0
.0
1
−0
.2
4
p
-V
a
lu
e
0
.2
8
0
.3
3
0
.6
8
0
.3
3
0
.1
4
0
.7
3
0
.4
7
0
.0
1
0
.0
4
0
.9
7
0
.3
1
N
o
n
-s
w
it
c
h
e
d
  
m
e
m
o
ry
 B
 c
e
lls
C
D
1
9
+ C
D
2
0
+ C
D
2
7
+ I
g
D
+
ρ
−0
.2
3
−0
.2
8
0
.0
6
0
.0
4
−0
.0
3
0
.2
3
−0
.0
1
−0
.0
4
−0
.0
7
0
.0
5
0
.0
3
p
-V
a
lu
e
0
.3
3
0
.2
3
0
.8
2
0
.8
6
0
.8
9
0
.3
2
0
.9
6
0
.8
8
0
.7
6
0
.8
5
0
.9
1
C
D
2
7
 +
 m
e
m
o
ry
  
B
 c
e
lls
C
D
1
9
+ C
D
2
0
+ C
D
2
7
+
ρ
−0
.3
1
−0
.4
1
0
.1
0
0
.1
0
−0
.1
7
0
.2
7
−0
.0
5
0
.1
5
−0
.2
6
0
.0
6
−0
.0
5
p
-V
a
lu
e
0
.1
9
0
.0
8
0
.6
8
0
.6
8
0
.4
8
0
.2
5
0
.8
4
0
.5
1
0
.2
7
0
.7
9
0
.8
4
P
la
s
m
a
b
la
s
ts
C
D
1
9
+ C
D
2
0
− C
D
3
8
h
i C
D
2
7
h
i Ig
D
− C
D
2
4
−
ρ
0
.3
4
0
.2
0
−0
.0
4
0
.0
3
−0
.3
5
0
.3
7
0
.1
0
0
.1
3
−0
.2
8
0
.5
2
0
.1
2
p
-V
a
lu
e
0
.1
4
0
.1
5
0
.8
8
0
.9
1
0
.1
3
0
.1
1
0
.6
7
0
.5
9
0
.2
4
0
.0
2
0
.6
2
D
o
u
b
le
 n
e
g
a
ti
v
e
  
m
e
m
o
ry
 B
 c
e
lls
C
D
1
9
+ C
D
2
0
+ I
g
D
− C
D
2
7
−
ρ
−0
.2
5
−0
.0
7
−0
.1
5
−0
.1
1
−0
.3
5
0
.1
9
−0
.1
2
0
.3
5
−0
.2
8
0
.4
4
−0
.0
4
p
-V
a
lu
e
0
.3
0
0
.7
7
0
.5
3
0
.6
4
0
.1
3
0
.4
3
0
.6
3
0
.1
4
0
.2
4
0
.0
6
0
.8
8
S
ta
ti
s
ti
c
a
lly
 s
ig
n
ifi
c
a
n
t 
c
o
rr
e
la
ti
o
n
 i
s
 s
h
o
w
n
 i
n
 b
o
ld
e
d
 v
a
lu
e
s
 w
it
h
 s
h
a
d
in
g
.
p
-V
a
lu
e
s
 <
0
.0
5
 i
n
d
ic
a
te
s
 a
 p
-v
a
lu
e
 b
e
tw
e
e
n
 0
.0
1
 a
n
d
 0
.0
5
.
T
A
B
L
E
 4
 |
 A
 c
o
m
p
a
ri
s
o
n
 o
f 
a
b
s
o
lu
te
 s
e
ru
m
 l
e
v
e
ls
 (
μg
/m
L
) 
a
n
d
 p
ro
p
o
rt
io
n
s
 o
f 
Ig
G
 s
u
b
c
la
s
s
e
s
 (
%
Ig
G
) 
v
s
. 
%
T
re
g
 o
r 
%
T
fr
 c
e
lls
 i
n
 i
n
d
iv
id
u
a
ls
 w
it
h
 c
lin
ic
a
lly
 i
s
o
la
te
d
 s
y
n
d
ro
m
e
 (
n
 =
 2
0
).
P
h
e
n
o
ty
p
e
S
ta
ti
s
ti
c
Ig
A
Ig
M
T
o
ta
l 
Ig
G
C
a
lc
u
la
te
d
 
Ig
G
1
Ig
G
2
Ig
G
3
Ig
G
4
C
a
lc
u
la
te
d
 
Ig
G
1
%
 I
g
G
Ig
G
2
%
 I
g
G
Ig
G
3
%
Ig
G
Ig
G
4
%
 I
g
G
F
rI
 T
re
g
 (
%
T
re
g
)
C
D
3
+ C
D
4
+ C
X
C
R
5
− F
o
x
P
3
lo
C
D
4
5
R
A
+  
T
re
g
ρ
−0
.0
8
0
.3
9
0
.3
0
0
.0
9
0
.1
3
0
.0
9
0
.1
1
−0
.0
1
−0
.0
3
−0
.1
1
0
.0
6
p
-V
a
lu
e
0
.7
3
0
.0
9
0
.2
0
0
.7
4
0
.6
0
0
.7
2
0
.6
5
0
.9
7
0
.9
0
0
.6
4
0
.8
1
F
rI
I 
T
re
g
 (
%
T
re
g
)
C
D
3
+ C
D
4
+ C
X
C
R
5
− F
o
x
P
3
h
i C
D
4
5
R
A
−  
T
re
g
ρ
0
.2
2
−0
.1
3
0
.2
1
0
.3
8
0
.0
8
0
.1
2
0
.0
4
0
.1
6
−0
.2
1
−0
.0
2
0
.0
0
3
p
-V
a
lu
e
0
.3
6
0
.6
0
0
.3
7
0
.1
3
0
.7
4
0
.6
1
0
.8
8
0
.5
0
0
.3
7
0
.9
4
0
.9
9
F
rI
II 
n
o
n
-T
re
g
 (
%
T
re
g
)
C
D
3
+ C
D
4
+ C
X
C
R
5
− F
o
x
P
3
lo
C
D
4
5
R
A
−  
T
re
g
ρ
−0
.0
6
−0
.2
0
−0
.5
7
−0
.3
0
−0
.1
4
−0
.1
8
−0
.0
1
−0
.3
1
0
.3
9
0
.2
3
0
.1
1
p
-V
a
lu
e
0
.8
0
0
.3
9
<0
.0
1
0
.2
4
0
.5
7
0
.4
5
0
.9
6
0
.1
9
0
.0
9
0
.3
2
0
.6
5
F
rI
 T
fr
 (
%
T
fr
)
C
D
3
+ C
D
4
+ C
X
C
R
5
+ F
o
x
P
3
lo
C
D
4
5
R
A
+ T
fr
ρ
−0
.0
7
0
.4
4
0
.1
4
−0
.0
3
0
.1
3
0
.1
2
−0
.0
0
3
−0
.1
3
0
.0
6
0
.0
7
0
.0
4
p
-V
a
lu
e
0
.7
7
0
.0
5
0
.5
7
0
.9
3
0
.5
9
0
.6
0
0
.9
9
0
.5
9
0
.8
2
0
.7
8
0
.8
8
F
rI
I 
T
fr
 (
%
T
fr
)
C
D
3
+ C
D
4
+ C
X
C
R
5
+ F
o
x
P
3
h
i C
D
4
5
R
A
−  
T
fr
ρ
0
.0
0
1
−0
.2
2
0
.2
1
0
.1
2
0
.0
4
0
.3
3
−0
.0
6
0
.1
0
−0
.1
0
.1
0
5
−0
.1
4
p
-V
a
lu
e
0
.1
0
0
.3
6
0
.3
7
0
.6
6
0
.8
8
0
.1
5
0
.8
0
0
.6
8
0
.5
2
0
.6
6
0
.5
6
F
rI
II 
n
o
n
-T
fr
 (
%
T
fr
)
C
D
3
+ C
D
4
+ C
X
C
R
5
+ F
o
x
P
3
lo
C
D
4
5
R
A
−  
T
fr
ρ
0
.0
2
−0
.2
4
−0
.3
6
0
.0
1
−0
.2
1
−0
.3
8
0
.1
3
0
.0
3
0
.0
7
−0
.0
5
0
.1
6
p
-V
a
lu
e
0
.9
2
0
.3
1
0
.1
2
0
.9
8
0
.3
7
0
.1
0
0
.5
7
0
.8
9
0
.7
7
0
.8
2
0
.5
1
S
ta
ti
s
ti
c
a
lly
 s
ig
n
ifi
c
a
n
t 
c
o
rr
e
la
ti
o
n
 i
s
 s
h
o
w
n
 i
n
 b
o
ld
e
d
 v
a
lu
e
s
 w
it
h
 s
h
a
d
in
g
.
11
Trend et al. Serum Igs in MS
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1590
ETHICS STATEMENT
This study was carried out in accordance with the recommenda-
tions of the National Health and Medical Research Council of 
Australia’s National Statement on Ethical Conduct in Human 
Research. The PhoCIS study protocol was approved by the 
Bellberry Human Research Ethics committee (2014-02-083) and 
endorsed by the Human Research Ethics Office of the University 
of Western Australia (RA/4/1/6796), and the study of MS par-
ticipants was approved by Sir Charles Gairdner Hospital Human 
Research Ethics Committee (2006-073). All participants gave 
written informed consent in accordance with the Declaration of 
Helsinki prior to study procedures being performed.
AUTHOR CONTRIBUTIONS
ST wrote the first draft of the paper. All the authors contributed 
to the drafting and editing the manuscript and approved the final 
version. PH, AK, SB, RL, DB, WC, and JC conceived the idea to 
perform the analysis of cells and Ig in blood from people with 
CIS and their subsequent conversion to MS. ST, SB, AJ, and PH 
designed the experiments. ST, AJ, SG, and LC performed the 
experiments. MF-P, JC, and AK contributed participant data. 
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